Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aethlon files cancer diagnostic patent
Researchers recently discovered that the Aethlon hemopurifier captures tumor secreted exosomes that inhibit the ability of the immune system to combat cancer. Based on emerging data, Aethlon believes
Researchers recently discovered that the Aethlon hemopurifier captures tumor secreted exosomes that inhibit the ability of the immune system to combat cancer. Based on emerging data, Aethlon believes
In conjunction with the series C financing, Bruce Robertson and Michael Wasserman of HIG Ventures will join Alex Zisson and James Thomas from Thomas, McNerney & Partners and
Singulex’s proprietary advanced biomarker detection technologies and optimized immunoassays are incorporated into Erenna, the company’s flagship biomarker detection platform system. Erenna and accompanying assays are designed to measure
The Motion study is a six-month (24-week), randomized, double-blind, international Phase III trial that will involve more than 650 patients with early idiopathic Parkinson’s disease (less than five
According to the company, SB1317 is designed to selectively inhibit major signalling pathways involving Flt3 and CDK, which impact disease progression in acute leukemias. By inhibiting both Flt3
This double-blind placebo-controlled crossover study will seek to detect a beneficial effect on bladder function in patients with secondary progressive multiple sclerosis, following open-label observations over several years
The technology used in the trial, the Lauriad buccal muco-adhesive tablet, has already proved itself in the company’s Loramyc product. The healing time of herpes lesions after taking
The EU approval of Tasigna was based on a pivotal clinical trial evaluating the rates of cytogenetic response (reduction or elimination of the Philadelphia chromosome) and confirmed hematologic
The clinical trial authorization (CTA) covers two multi-center pivotal Phase III efficacy studies followed by an open label safety study. Patient enrolment in the UK is expected to
According to Xceed’s president and CEO, David Deems, the Strategic Collaborator program is a mutually beneficial agreement with a high-profile institution or investigator designed to propel the partners’